Related Experiment Video
Updated: Oct 30, 2025
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
Published on: June 18, 2013
Biparatopic Protein Nanoparticles for the Precision Therapy of CXCR4+ Cancers
Olivia Cano-Garrido1,2, Patricia Álamo3,4,5, Laura Sánchez-García2,3,6
1Nanoligent SL, Edifici EUREKA, Universitat Autònoma de Barcelona, Bellaterra, 08193 Barcelona, Spain.
Abstract:
The accumulated molecular knowledge about human cancer enables the identification of multiple cell surface markers as highly specific therapeutic targets. A proper tumor targeting could significantly avoid drug exposure of healthy cells, minimizing side effects, but it is also expected to increase the therapeutic index. Specifically, colorectal cancer has a particularly poor prognosis in late stages, being drug targeting an appropriate strategy to substantially improve the therapeutic efficacy. In this study, we have explored the potential of the human albumin-derived peptide, EPI-X4, as a suitable ligand to target colorectal cancer via the cell surface protein CXCR4, a chemokine receptor overexpressed in cancer stem cells. To explore the potential use of this ligand, self-assembling protein nanoparticles have been generated displaying an engineered EPI-X4 version, which conferred a modest CXCR4 targeting and fast and high level of cell apoptosis in tumor CXCR4+ cells, in vitro and in vivo. In addition, when EPI-X4-based building blocks are combined with biologically inert polypeptides containing the CXCR4 ligand T22, the resulting biparatopic nanoparticles show a dramatically improved biodistribution in mouse models of CXCR4+ human cancer, faster cell internalization and enhanced target cell death when compared to the version based on a single ligand. The generation of biparatopic materials opens exciting possibilities in oncotherapies based on high precision drug delivery based on the receptor CXCR4.
Insights
Researchers developed novel protein nanoparticles targeting colorectal cancer. These nanoparticles, utilizing the EPI-X4 peptide and biparatopic strategies, show enhanced tumor cell death and improved drug delivery for cancer therapy.
Area of Science:
- Biotechnology
- Oncology
- Nanomedicine
Background:
- Molecular understanding of human cancers reveals specific cell surface markers for targeted therapies.
- Colorectal cancer (CRC) presents a poor prognosis in advanced stages, necessitating improved therapeutic strategies.
- CXCR4, a chemokine receptor, is overexpressed on cancer stem cells and serves as a potential therapeutic target.
Purpose of the Study:
- To evaluate the potential of the human albumin-derived peptide EPI-X4 as a ligand for targeting CXCR4-expressing colorectal cancer.
- To engineer self-assembling protein nanoparticles displaying EPI-X4 for enhanced cancer targeting and therapeutic efficacy.
- To investigate the synergistic effects of biparatopic nanoparticles combining EPI-X4 and T22 ligands for improved cancer therapy.
Main Methods:
- Generation of self-assembling protein nanoparticles displaying an engineered EPI-X4 variant.
- In vitro and in vivo assessment of nanoparticle targeting, cell apoptosis, and biodistribution in CXCR4-positive cancer models.
- Construction and evaluation of biparatopic nanoparticles by combining EPI-X4 and T22 ligand-functionalized polypeptides.
Main Results:
- EPI-X4-displaying nanoparticles demonstrated modest CXCR4 targeting and induced rapid, high-level apoptosis in CXCR4+ tumor cells.
- Biparatopic nanoparticles incorporating both EPI-X4 and T22 ligands exhibited significantly improved biodistribution in mouse cancer models.
- These biparatopic constructs showed faster cell internalization and enhanced target cell death compared to single-ligand nanoparticles.
Conclusions:
- Engineered EPI-X4-based protein nanoparticles are promising for targeting CXCR4-expressing colorectal cancer.
- Biparatopic nanoparticle design significantly enhances targeting, cellular uptake, and therapeutic efficacy against CXCR4+ cancers.
- This approach offers a novel strategy for precision drug delivery in oncotherapy via the CXCR4 receptor.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...